On October 6, 2026, Envoy Medical, Inc., a Delaware corporation (the "Company"), entered into a Dismissal Agreement (the "Dismissal Agreement") regarding litigation in the Delaware Court of Chancery (the "Litigation") with Atlas Merchant Capital SPAC Fund I LP ("Atlas") related to Atlas’ allegation that it was not allowed to redeem its shares of Class A Common Stock in the Company’s September 2023 business combination transaction.

Pursuant to the terms of the Dismissal Agreement, all of Atlas’ claims will be dismissed with prejudice, and there will be no further proceedings in relation to the Litigation. In addition, neither the Company nor any other defendant will be required to make a payment to Atlas under the Dismissal Agreement.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.